Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HPN328 |
Synonyms | |
Therapy Description |
HPN328 is a tri-specific molecule that simultaneously binds to DLL3 on tumor cells and CD3 on T cells, potentially resulting in an upregulation and activation of T cells and subsequent increased death of DLL3-expressing tumor cells (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C033). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HPN328 | TriTAC HPN328|HPN-328|DLL3/CD3e TriTAC HPN328|Anti-DLL3 T-cell Engager HPN328 | HPN328 is a tri-specific molecule that simultaneously binds to DLL3 on tumor cells and CD3 on T cells, potentially resulting in an upregulation and activation of T cells and subsequent increased death of DLL3-expressing tumor cells (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C033). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04471727 | Phase Ib/II | Atezolizumab + HPN328 HPN328 | Study in Patients With Advanced Cancers Associated With Expression of DLL3 | Recruiting | USA | 0 |